Eisai Co., Ltd.
Fiscal 2026 Q2 (Interim) Earnings Presentation
Revenue 470 billion yen (YoY +17.5%), operating income 41.4 billion yen (YoY +20.4%), core operating income 43.1 billion yen (+28.6%), driven by growth of the three key 3L products. Full-year forecast: revenue 883.5 billion yen, operating income 70.0 billion yen, with progress rates of 53.2% and 59.2% respectively.
Key Figures
- Revenue: 4,700 (hundred million yen) Year-over-Year +17.5%
- Operating Income: 414 (hundred million yen) Year-over-Year +20.4%
- Core Operating Income: 431 (hundred million yen) Year-over-Year +28.6%
AI要約
Summary of Results
Pharmaceutical operations expanded significantly this period, led by growth of the 3L products (LENVIMA, DAYVIGO, LEQEMBI). Revenue reached 470 billion yen (YoY +17.5%), operating income was 41.4 billion yen (+20.4%), and core operating income was 43.1 billion yen (+28.6%), achieving double-digit profit growth. Contributions from key products supported solid growth across multiple global markets.
Outlook and Impact for Investors
The full-year forecast is revenue of 883.5 billion yen and operating income of 70.0 billion yen, with progress at 53.2% and 59.2% respectively. Growth centered on the 3L franchise is expected to continue, particularly in the U.S., Japan, and China where new indications and launches are progressing. For investors, the growth foundation established in H1 FY2026 is solid, and further contributions to results are anticipated in H2 and beyond.
Revenue Trend
Operating Income Trend
Core Operating Income Trend
Margin Analysis
Forecast vs. Actual Comparison
Eisai Co., Ltd.
Company overview · Stock price · Financial data · All IR
